US Pharma MarketingThe post Relay Therapeutics reports initial findings from Phase II ReInspire trial appeared first on Clinical Trials Arena.
Relay Therapeutics reports initial findings from Phase II ReInspire trial
Relay Therapeutics has reported initial findings from its Phase II ReInspire trial evaluating zovegalisib in patients with PIK3CA-driven vascular anomalies, underlining the role of PI3Kα mutant-selective inhibition. In Part I, 32 patients aged 12 years and above were enrolled and received 100mg, 300mg, or 400mg twice daily. Out of 20 efficacy-evaluable patients, 60% showed a volumetric response at the first MRI assessment. Credit: Gorodenkoff / Shutterstock.com. Relay Therapeutics has reported initial findings from its Phase II ReInspire trial evaluating zovegalisib in patients with phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA)-driven vascular anomalies, underlining the role of PI3Kα mutant-selective inhibition. The interim…
Relay Therapeutics has reported initial findings from its Phase II ReInspire trial evaluating zovegalisib in patients with PIK3CA-driven vascular anomalies, underlining the role of PI3Kα mutant-selective inhibition.
Source: Clinical Trials Arena